KT said it would provide information communication technology (ICT) platform capabilities such as artificial intelligence, big data and cloud to upgrade an environment for genetic information analysis and storage management. NGeneBio will provide customized health care coaching services to KT customers using technologies.
NGeneBio, founded in 2015 as a joint venture between Genecurix and KT, provides next-generation sequencing (NGS)-based in vitro diagnostics products. The two companies would cooperate for the development of personalized health care services, the establishment of specialized platforms for storing and managing personal genetic analysis information, and the development of big data analysis services for genetic information.
"We will further strengthen our genetic analysis capabilities and develop a platform for the management and interlocking of personal genetic analysis information," said NGeneBio CEO Choi Dae-chul.
KT has selected digital and bio-health services using ICT as the core of its future strategy. The company works with health and medical institutions to establish an ICT-based health business models and advance into poor medical conditions. Three days ago, KT forged a strategic partnership with Medical Partners Korea to push for a digital healthcare and medical Informatization project abroad.
Medical Partners Korea has operated an outpatient general hospital and an entrusted inspection center in Kazakhstan. In March, it was designated as an inspection agency for COVID-19 molecular diagnostics.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.